MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.090
-0.130
-4.04%
Opening 10:17 03/03 EST
OPEN
3.280
PREV CLOSE
3.220
HIGH
3.300
LOW
3.070
VOLUME
127.41K
TURNOVER
--
52 WEEK HIGH
6.48
52 WEEK LOW
1.600
MARKET CAP
24.80M
P/E (TTM)
-0.3944
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Phio Pharmaceuticals Shares Quiet; Co Granted U.S. Patent Titled 'Immunotherapy of cancer'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=10934550&OS=10934550&RS=10934550
Benzinga · 1d ago
Thinking about buying stock in Phio Pharmaceuticals, SRAX Inc, KemPharm, Avadel Pharmaceuticals, or Neovasc Inc?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, SRAX, KMPH, AVDL, and NVCN.
PR Newswire - PRF · 2d ago
Phio Pharma Shares Are Trading Higher On Cancer Immunotherapies Pact With AgonOx
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has 
Benzinga · 2d ago
Phio Pharmaceuticals shares rise after Agonox research deal
Phio Pharmaceuticals (PHIO) shares jump nearly 12% premarket after announcing that it has entered into a clinical development collaboration with AgonOx to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL
Seekingalpha · 2d ago
BRIEF-Phio Pharmaceuticals, AgonOx Inc Announce Collaboration on Development of Cancer Immunotherapies
reuters.com · 2d ago
SSYS, MARA, SOS and CAN among premarket gainers
ASLAN Pharmaceuticals Limited (ASLN +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR +39% on ex...
Seekingalpha · 2d ago
Phio Pharmaceuticals And AgonOx, Inc. Announce Collaboration On Clinical Development Of Novel T Cell-based Cancer Immunotherapies; Financial Details Not Disclosed
MARLBOROUGH, Mass., March 1, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary
Benzinga · 2d ago
Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th
PR Newswire - PRF · 02/23 12:30
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIO. Analyze the recent business situations of Phio Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHIO stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 959.49K
% Owned: 11.95%
Shares Outstanding: 8.03M
TypeInstitutionsShares
Increased
2
85.18K
New
12
119.92K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.90%
Pharmaceuticals & Medical Research
-1.93%
Key Executives
Chairman/Director
Robert Bitterman
President/Chief Executive Officer/Chief Operating Officer
Gerrit Dispersyn
Other
John Barrett
Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
  • Dividends
  • Splits
  • Insider Activity
No Data
About PHIO
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.